The innovative drug YUVEZZI™ (2.75% carbachol and 0.1% brimonidine tartrate ophthalmic solution) from Zhaoke Ophthalmology-B (06622) has received approval from the Macau Special Administrative Region's Pharmaceutical Administration for the treatment of presbyopia.

The company is actively pursuing the inclusion of YUVEZZI™ in the "Macau-Hong Kong Drug and Medical Device Access" program, with the goal of facilitating the product's clinical use in the Greater Bay Area at the earliest opportunity.

Zhaoke Ophthalmology-B is committed to providing efficient access pathways for innovative presbyopia treatment options, aiming to benefit more patients as quickly as possible.